This upregulation requires ERK activity and inhibition of p38 and was also observed in other cancer cells carrying KRAS, BRAF, or NF1 mutations, suggesting that p38 antagonizes this resistance pathway in several different cancer types. The gene discussed is BRAF; the disease is cancer.